CLPT ClearPoint Neuro Inc

Price (delayed)

$14.31

Market cap

$429.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1

Enterprise value

$457.15M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 19

ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of ...

Highlights
The gross profit has grown by 28% YoY and by 12% from the previous quarter
ClearPoint Neuro's revenue has increased by 26% YoY and by 10% from the previous quarter
The quick ratio has soared by 100% YoY but it has contracted by 4.1% from the previous quarter
ClearPoint Neuro's net income has decreased by 40% YoY and by 14% from the previous quarter
The equity has contracted by 33% from the previous quarter and by 6% YoY

Key stats

What are the main financial stats of CLPT

CLPT stock price

How has the ClearPoint Neuro stock price performed over time
Intraday
7.59%
1 week
16.91%
1 month
28%
1 year
10.16%
YTD
4.61%
QTD
57.25%

Financial performance

How have ClearPoint Neuro's revenue and profit performed over time
Revenue
$40.61M
Gross profit
$25.32M
Operating income
-$26.48M
Net income
-$29.07M
Gross margin
62.3%
Net margin
-71.6%
ClearPoint Neuro's net income has decreased by 40% YoY and by 14% from the previous quarter
The gross profit has grown by 28% YoY and by 12% from the previous quarter
ClearPoint Neuro's revenue has increased by 26% YoY and by 10% from the previous quarter
The company's operating income fell by 22% YoY and by 10% QoQ

Price vs fundamentals

How does CLPT's price correlate with its fundamentals

Growth

What is ClearPoint Neuro's growth rate over time

Valuation

What is ClearPoint Neuro stock price valuation
P/E
N/A
P/B
22.53
P/S
10.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.26
ClearPoint Neuro's EPS has decreased by 32% YoY and by 11% from the previous quarter
The P/B is 98% above the 5-year quarterly average of 10.6
The equity has contracted by 33% from the previous quarter and by 6% YoY
ClearPoint Neuro's revenue has increased by 26% YoY and by 10% from the previous quarter
The price to sales (P/S) is 20% lower than the 5-year quarterly average of 12.1 and 14% lower than the last 4 quarters average of 11.3

Efficiency

How efficient is ClearPoint Neuro business performance
The return on equity has dropped by 81% year-on-year and by 15% since the previous quarter
ClearPoint Neuro's return on invested capital has surged by 74% YoY and by 22% QoQ
CLPT's ROA is up by 28% YoY and by 9% from the previous quarter

Dividends

What is CLPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLPT.

Financial health

How did ClearPoint Neuro financials performed over time
The company's total assets is 25% higher than its total liabilities
The quick ratio has soared by 100% YoY but it has contracted by 4.1% from the previous quarter
The current ratio has soared by 64% YoY but it has contracted by 2% from the previous quarter
The debt to equity has surged by 62% since the previous quarter
The equity has contracted by 33% from the previous quarter and by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.